CASI Pharmaceuticals, Inc.
Source: CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer
CASI Pharmaceuticals, Inc.
Source: CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer
No comments:
Post a Comment